Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos

Regulatory Affairs
Return to: PBR Home | Regulatory Affairs | News
Search Refinements

Regulatory Affairs News

View news from other Pharmaceutical sectors:
1-15 of 3353 results
FDA approves Relistor tablets to treat OIC in chronic non-cancer pain adults
By PBR Staff Writer
The US Food and Drug Administration has approved Relistor (methylnaltrexone bromide) tablets to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Regulatory Affairs > News
FDA approves expanded label for NAMZARIC to treat moderate to severe Alzheimer's disease
Allergan and Adamas Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved a new, expanded label for NAMZARIC (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI).
Regulatory Affairs > News
European Commission approves AstraZeneca’s Qtern to treat type 2 diabetes
By PBR Staff Writer
AstraZeneca has secured approval from the European Commission (EC) for Qtern tablets to treat type 2 diabetes.
Regulatory Affairs > News
Perrigo wins FDA approval fo romeprazole and sodium bicarbonate capsules, 20mg/1100mg
The U.S. Food and Drug Administration has approved Perrigo's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg.
Regulatory Affairs > News
Fera Pharmaceuticals and Oakwood Labs announce ANDA approval of Levothyroxine Sodium for Injection
Fera Pharmaceuticals and Oakwood Laboratories announced that on June 29, 2016, the FDA approved their ANDA for 100 and 500 mcg Levothyroxine Sodium for Injection.
Regulatory Affairs > News
Celgene’s Revlimid approved in Europe for relapsed or refractory mantle cell lymphoma
By PBR Staff Writer
Celgene has secured approval from the European Commission for Revlimid (lenalidomide) to treat patients with relapsed/refractory mantle cell lymphoma (MCL).
Regulatory Affairs > News
Eisai and Arena Pharmaceuticals secure regulatory approval of VENESPRI in Mexico
Eisai and Arena Pharmaceuticals announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the chronic weight management agent VENESPRI (lorcaserin HCl: U.S. brand name: BELVIQ) for commercialization by Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico) in Mexico.
Regulatory Affairs > News
Shire’s Xiidra secures FDA approval for dry eye disease
By PBR Staff Writer
Shire has secured approval from the US Food and Drug Administration (FDA) for its Xiidra (lifitegrast ophthalmic solution) to treat signs and symptoms of dry eye disease.
Regulatory Affairs > News
Gilead secures EC marketing authorization for Epclusa to treat all genotypes of chronic hepatitis C
By PBR Staff Writer
The European Commission (EC) has granted marketing authorization for Gilead Sciences’ Epclus (sofosbuvir 400 mg/velpatasvir 100 mg) to treat all genotypes of chronic hepatitis C.
Regulatory Affairs > News
UK’s NICE approves Pfizer’s Bosulif for chronic myeloid leukaemia
By PBR Staff Writer
The UK’s National Institute for Health and Care Excellence (NICE) has approved Pfizer’s Bosulif (bosutinib) to treat some people with chronic myeloid leukaemia (CML).
Regulatory Affairs > News
Shire gets extension of market authorization in Europe for Revestive to treat paediatric patients with SBS
The European Commission has granted extension of Market Authorization for Shire's Revestive (teduglutide) 5 mg powder and solvent for solution for injection for the treatment of patients aged one year and above with Short Bowel Syndrome (SBS).
Regulatory Affairs > News
EC approves Adcetris as consolidation treatment in post-transplant hodgkin lymphoma
By PBR Staff Writer
The European Commission (EC) has approved Adcetris (brentuximab vedotin) for use as a consolidation therapy to treat adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT).
Regulatory Affairs > News
European Commission approves Zinbryta to treat relapsing forms of multiple sclerosis
The European Commission (EC) has approved Zinbryta (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS).
Regulatory Affairs > News
EC approves extended indication for Amgen's Kyprolis to treat relapsed multiple myeloma
By PBR Staff Writer
The European Commission (EC) has approved extended indication for Amgen's Kyprolis (Carfilzomib) to treat patients with relapsed multiple myeloma.
Regulatory Affairs > News
EC grants orphan drug status to Mereo's BPS-804 for osteogenesis imperfecta
By PBR Staff Writer
Mereo BioPharma Group announced that its drug BPS-804 has been granted orphan drug designation by the European Commission (EC) in the treatment of osteogenesis imperfecta (OI).
Regulatory Affairs > News
1-15 of 3353 results